Hims to Stop Offering GLP-1 Pill After FDA Warned of Crackdown

UNTED STATES – Online telehealth company Hims & Hers is backing off plans to sell a 49-dollar compounded version of Novo Nordisk’s weight-loss drug Wegovy after warning signs from federal regulators.

The U.S. Food and Drug Administration says it will move to restrict GLP-1 ingredients used in compounded drugs, citing concerns about quality, safety and possible violations of federal law.

The Department of Health and Human Services says it will refer the matter to the Department of Justice.

News of the proposed low-cost copycat pill, first reported by Reuters, sparked a selloff in shares of Novo and rival Eli Lilly before some recovery Friday.

The FDA commissioner says the agency is taking a hard line as it weighs cracking down on compounded weight-loss drugs.